James L. Cox - Mar 20, 2025 Form 4 Insider Report for Adagio Medical Holdings, Inc. (ADGM)

Role: Director
Signature: /s/ John Dahldorf, Attorney-in-Fact
Stock symbol: ADGM
Transactions as of: Mar 20, 2025
Transactions value $: $0
Form type: 4
Date filed: 3/21/2025, 07:00 PM
Previous filing: Feb 21, 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADGM	Non-qualified stock option (right to buy)	Award	$0	+90K		$0.00	90K	Mar 20, 2025	Common Stock	90K	$0.87	Direct	F1
transaction	ADGM	Non-qualified stock option (right to buy)	Award	$0	+364K		$0.00	364K	Mar 20, 2025	Common Stock	364K	$0.87	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Stock option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Option will vest over a three-year period, whereby 1/36th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of July 31, 2024.
F2	Stock Option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Special Option"). Special Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Special Option is vested in full as of the grant date.

Content

Stock option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Option will vest over a three-year period, whereby 1/36th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of July 31, 2024.

Stock Option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Special Option"). Special Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Special Option is vested in full as of the grant date.